{"DataElement":{"publicId":"6776720","version":"1","preferredName":"Lymphoma Histologic Classification Type","preferredDefinition":"The type of histologic classification of lymphoma.","longName":"6775427v1.0:6775791v1.0","context":"Alliance","contextVersion":"1","DataElementConcept":{"publicId":"6775427","version":"1","preferredName":"Lymphoma Histologic Classification","preferredDefinition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas._Pertaining to the combined microscopic physical features of cells and their surrounding extracellular environment in tissues._A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","longName":"2475110v1.0:2207691v1.0","context":"Alliance","contextVersion":"1","ObjectClass":{"publicId":"2475110","version":"1","preferredName":"Lymphoma","preferredDefinition":"A malignant (clonal) proliferation of B- or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites.  This category includes Non-Hodgkin's lymphomas and Hodgkin's lymphomas. -- 2003","longName":"C3208","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphoma","conceptCode":"C3208","definition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"11901624-1EB2-3055-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-16","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-04-16","modifiedBy":"ONEDATA","dateModified":"2006-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2207691","version":"1","preferredName":"Histologic Classification","preferredDefinition":"Of or relating to histology.:Classification; the grouping of things into classes or categories.","longName":"C25526:C25161","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Histologic","conceptCode":"C25526","definition":"Pertaining to the combined microscopic physical features of cells and their surrounding extracellular environment in tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Classification","conceptCode":"C25161","definition":"A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-2C90-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8AA7BAF1-BD74-28F7-E053-F662850A7ECD","latestVersionIndicator":"Yes","beginDate":"2019-06-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-06-06","modifiedBy":"MORENOC","dateModified":"2019-11-07","changeDescription":"11/7/2019: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6775791","version":"1","preferredName":"Lymphoma Histologic Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"6775791v1.0","context":"Alliance","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"DHL: High-grade B-cell lymphoma with translocations of MYC and BCL6 (Double Hit Lymphoma) PLUS BCL2 expression by immunohistochemistry","valueDescription":"High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements Additional BCL2 Positive From Immunohistochemistry","ValueMeaning":{"publicId":"6775794","version":"1","preferredName":"High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements Additional BCL2 Positive From Immunohistochemistry","longName":"6775794","preferredDefinition":"A rare B-cell non-Hodgkin lymphoma that is characterized by the abnormal rearrangement of two genes, MYC gene and either BCL2 or BCL6 genes. Patients with this type of lymphoma usually respond poorly to standard treatments and have a poor prognosis.: Added; extra; further.: An indication that BCL2 expression has been detected in a sample.: Used to indicate a specified place or time as a starting point; used to indicate a source, cause, agent, or instrument.: Histochemical localization of immunoreactive substances using labeled antibodies as reagents. (MSH98)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements","conceptCode":"C125904","definition":"High-grade B-cell lymphoma characterized by the abnormal rearrangement of two genes, MYC gene and either BCL2 or BCL6 genes. Patients with this type of lymphoma usually respond poorly to standard treatments and have a poor prognosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Additional","conceptCode":"C25406","definition":"Added; extra; further.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"BCL2 Positive","conceptCode":"C134463","definition":"An indication that BCL2 expression has been detected in a sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"From","conceptCode":"C25516","definition":"Used to indicate a specified place or time as a starting point; used to indicate a source, cause, agent, or instrument.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Immunohistochemistry","conceptCode":"C16722","definition":"Histochemical localization of immunoreactive substances using labeled antibodies as reagents. (MSH98)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8AA9F65F-AA35-35C2-E053-F662850A5532","latestVersionIndicator":"Yes","beginDate":"2019-06-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-06-06","modifiedBy":"ONEDATA","dateModified":"2019-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8AA9F65F-AA4E-35C2-E053-F662850A5532","beginDate":"2019-06-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-06-06","modifiedBy":"ONEDATA","dateModified":"2019-06-06","deletedIndicator":"No"},{"value":"DHL: High-grade B-cell lymphoma with translocations of MYC and BCL2 (Double Hit Lymphoma)","valueDescription":"High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements","ValueMeaning":{"publicId":"6773704","version":"1","preferredName":"High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements","longName":"6773704","preferredDefinition":"A rare B-cell non-Hodgkin lymphoma that is characterized by the abnormal rearrangement of two genes, MYC gene and either BCL2 or BCL6 genes. Patients with this type of lymphoma usually respond poorly to standard treatments and have a poor prognosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements","conceptCode":"C125904","definition":"High-grade B-cell lymphoma characterized by the abnormal rearrangement of two genes, MYC gene and either BCL2 or BCL6 genes. Patients with this type of lymphoma usually respond poorly to standard treatments and have a poor prognosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8A6AE344-70E7-6D00-E053-F662850A60A5","latestVersionIndicator":"Yes","beginDate":"2019-06-03","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-06-03","modifiedBy":"ONEDATA","dateModified":"2019-06-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8AA9F65F-AA62-35C2-E053-F662850A5532","beginDate":"2019-06-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-06-06","modifiedBy":"ONEDATA","dateModified":"2019-06-06","deletedIndicator":"No"},{"value":"DEL: High-grade B-cell lymphoma, NOS (Double Expressing Lymphoma)","valueDescription":"Double-Expressor Lymphoma High Grade B-Cell Lymphoma, Not Otherwise Specified","ValueMeaning":{"publicId":"6775797","version":"1","preferredName":"Double-Expressor Lymphoma High Grade B-Cell Lymphoma, Not Otherwise Specified","longName":"6775797","preferredDefinition":"A diffuse large B-cell lymphoma characterized by double expression of MYC and BCL2 proteins without MYC and BCL2 gene aberrations. These lymphomas may have a worse prognosis than other diffuse large B-cell lymphomas, not otherwise specified, but they are not as aggressive as the high-grade B-cell lymphomas, with rearrangements of MYC and BCL2 and/or BCL6 genes.: A high grade B-cell lymphoma with blastoid features or features between diffuse large B-cell lymphoma and Burkitt lymphoma which lacks MYC, BCL2, and BCL6 rearrangements.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Double-Expressor Lymphoma","conceptCode":"C138899","definition":"A diffuse large B-cell lymphoma characterized by double expression of MYC and BCL2 proteins without MYC and BCL2 gene aberrations. These lymphomas may have a worse prognosis than other diffuse large B-cell lymphomas, not otherwise specified, but they are not as aggressive as the high-grade B-cell lymphomas, with rearrangements of MYC and BCL2 and/or BCL6 genes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"High Grade B-Cell Lymphoma, Not Otherwise Specified","conceptCode":"C80291","definition":"High-grade B-cell lymphoma with blastoid features or features between diffuse large B-cell lymphoma and Burkitt lymphoma that lacks MYC, BCL2, and BCL6 gene rearrangements.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8AA9F65F-AA70-35C2-E053-F662850A5532","latestVersionIndicator":"Yes","beginDate":"2019-06-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-06-06","modifiedBy":"ONEDATA","dateModified":"2019-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8AA9F65F-AA89-35C2-E053-F662850A5532","beginDate":"2019-06-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-06-06","modifiedBy":"ONEDATA","dateModified":"2019-06-06","deletedIndicator":"No"},{"value":"DEL: Diffuse large B-cell lymphoma (DLBCL), NOS (Double Expressing Lymphoma)","valueDescription":"Double-Expressor Lymphoma Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","ValueMeaning":{"publicId":"6775800","version":"1","preferredName":"Double-Expressor Lymphoma Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","longName":"6775800","preferredDefinition":"A diffuse large B-cell lymphoma characterized by double expression of MYC and BCL2 proteins without MYC and BCL2 gene aberrations. These lymphomas may have a worse prognosis than other diffuse large B-cell lymphomas, not otherwise specified, but they are not as aggressive as the high-grade B-cell lymphomas, with rearrangements of MYC and BCL2 and/or BCL6 genes.: A term referring to a group of diffuse large B-cell lymphomas which are biologically heterogeneous. These lymphomas have a centroblastic, immunoblastic, or anaplastic morphology.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Double-Expressor Lymphoma","conceptCode":"C138899","definition":"A diffuse large B-cell lymphoma characterized by double expression of MYC and BCL2 proteins without MYC and BCL2 gene aberrations. These lymphomas may have a worse prognosis than other diffuse large B-cell lymphomas, not otherwise specified, but they are not as aggressive as the high-grade B-cell lymphomas, with rearrangements of MYC and BCL2 and/or BCL6 genes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","conceptCode":"C80280","definition":"A term referring to a group of diffuse large B-cell lymphomas which are biologically heterogeneous. These lymphomas have a centroblastic, immunoblastic, or anaplastic morphology.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8AA9F65F-AA96-35C2-E053-F662850A5532","latestVersionIndicator":"Yes","beginDate":"2019-06-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-06-06","modifiedBy":"ONEDATA","dateModified":"2019-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8AA9F65F-AAAF-35C2-E053-F662850A5532","beginDate":"2019-06-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-06-06","modifiedBy":"ONEDATA","dateModified":"2019-06-06","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8AA9F65F-AA19-35C2-E053-F662850A5532","latestVersionIndicator":"Yes","beginDate":"2019-06-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-06-06","modifiedBy":"MORENOC","dateModified":"2019-11-07","changeDescription":"11/7/2019: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Histologic type","type":"Preferred Question Text","description":"Histologic type","url":null,"context":"Alliance"}],"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8AF52FBA-D6D5-1C62-E053-F662850ADC4F","latestVersionIndicator":"Yes","beginDate":"2019-06-10","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-06-10","modifiedBy":"MORENOC","dateModified":"2019-11-07","changeDescription":"11/7/2019: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}